title: Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence.
abstract: Methamphetamine (METH) is a strongly addictive psychostimulant that dramatically affects the central nervous system (CNS). On the other hand, protein kinase C (PKC) plays a major role in cellular regulatory and signalling processes that involve protein phosphorylation. The purpose of this study was to investigate the role of neuronal and astrocytic PKC in changes in the central glutamatergic system induced by METH. We show here that in vitro treatment with METH caused the phosphorylation of both neuronal and astrocytic PKC and the activation of astrocytes in cortical neuron/glia co-cultures. Treatment of cortical neuron/glia co-cultures with either the PKC activator phorbol 12,13-dibutyrate (PDBu) or glutamate also caused the PKC-dependent activation of astrocytes. The PKC inhibitor chelerythrine suppressed the Ca2+ responses to glutamate in both cortical neurons and astrocytes. Moreover, a low concentration of PDBu significantly enhanced the Ca2+ responses to glutamate, but not to dopamine, in both cortical neurons and astrocytes. Notably, treatment with METH also enhanced the Ca2+ responses to glutamate in cortical neurons. The activation of astrocytes induced by METH was also reversed by co-treatment with glutamate receptor antagonists (ifenprodil, DNQX or MPEP) in cortical neuron/glia co-cultures. In the conditioned place preference paradigm, intracerebroventricular administration of glutamate receptor antagonists (ifenprodil, DNQX or MPEP) attenuated the METH-induced rewarding effect. These findings provide evidence that the changes in PKC-dependent neuronal and astrocytic glutamatergic transmission induced by METH may, at least in part, contribute to the development of psychological dependence on METH.
authors.affiliation: Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawaku, Tokyo 142-8501, Japan.
authors.forename: Mayumi
authors.initials: M
authors.lastname: Miyatake
authors.forename: Minoru
authors.initials: M
authors.lastname: Narita
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shibasaki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakamura
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Suzuki
mesh_terms: D019969:Amphetamine-Related Disorders / Q000201:enzymology / Q000503:physiopathology*; D000818:Animals; D001253:Astrocytes / Q000502:physiology; D002118:Calcium / Q000378:metabolism / Q000502:physiology; D002450:Cell Communication / Q000502:physiology*; D000697:Central Nervous System Stimulants; D018920:Coculture Techniques; D003216:Conditioning, Operant / Q000187:drug effects; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005260:Female; D018698:Glutamic Acid / Q000502:physiology*; D007150:Immunohistochemistry; D008297:Male; D008694:Methamphetamine; D051379:Mice; D008813:Mice, Inbred ICR; D018613:Microscopy, Confocal; D009457:Neuroglia / Q000502:physiology*; D009474:Neurons / Q000502:physiology*; D010880:Piperidines / Q000494:pharmacology; D011247:Pregnancy; D011493:Protein Kinase C / Q000502:physiology*; D011725:Pyridines / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D017470:Receptors, Glutamate / Q000187:drug effects; D009435:Synaptic Transmission / Q000502:physiology*
chemical_list: D000697:Central Nervous System Stimulants; D018691:Excitatory Amino Acid Antagonists; D010880:Piperidines; D011725:Pyridines; D011810:Quinoxalines; D017470:Receptors, Glutamate; D018698:Glutamic Acid; D008694:Methamphetamine; C056723:FG 9041; C121465:6-methyl-2-(phenylethynyl)pyridine; D011493:Protein Kinase C; C010739:ifenprodil; D002118:Calcium